<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02428049</url>
  </required_header>
  <id_info>
    <org_study_id>2013/169</org_study_id>
    <nct_id>NCT02428049</nct_id>
  </id_info>
  <brief_title>Radiation Pneumonitis After SBRT for NSCLC</brief_title>
  <official_title>Lung Function After Curatively Intended Radiotherapy for Non-small-cell Lung Carcinoma, -Changes and Predictive Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sykehuset i Vestfold HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian Radium Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sykehuset i Vestfold HF</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aims:&#xD;
&#xD;
        1. Evaluate changes in lung function before and after radiotherapy for patients with NSCLC&#xD;
           in stage I-III receiving curatively intended radiotherapy&#xD;
&#xD;
        2. To assess the predictive value of pulmonary function tests for the development of&#xD;
           radiation pneumonitis after curative radiotherapy&#xD;
&#xD;
        3. To assess biomarkers in blood samples before, during, and after radiotherapy and&#xD;
           correlate to the development of radiation pneumonitis&#xD;
&#xD;
        4. Investigate survival&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective longitudinal study planned to include 70 patients with NSCLC in stages I-III&#xD;
      who will be its own control group for changes in lung function.&#xD;
&#xD;
      It will be included patients destined to have stereotactic or concomitant chemoradiotherapy&#xD;
      in curative intent.&#xD;
&#xD;
      Follow-up will include a physical examination by a pulmonologist, spirometry, determination&#xD;
      of the diffusion capacity for carbon monoxide (DLCO), determination of the total lung&#xD;
      capacity (TLC), residual volume (RV) and intrathoracic gas volume (ITGV) by body&#xD;
      plethysmography, determination of the partial pressure of carbon dioxide (PaCO2) and oxygen&#xD;
      (PaO2) by arterial blood gas analysis, the six-minute walking test, the Clinical COPD&#xD;
      questionnaire, X-ray and CT scans and blood sample analysis at baseline, 4 to 6 weeks after&#xD;
      treatment, and every 3 months thereafter until 12 months after SBRT.&#xD;
&#xD;
      Part of the project is to take blood samples. Specific blood samples will be analyzed to&#xD;
      identify biomarkers that could predict the development of radiation-induced lung changes.&#xD;
&#xD;
      Unfortunately, fewer patients than planned were included.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>permanently reduced lung function</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>predictive value of pulmonary function tests for the development of a permanent reduction in lung function after curative radiotherapy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>predictive value of genetic markers for permanently reduced lung function after curative radiotherapy</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">105</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Radiotherapy</condition>
  <condition>Lung Function Changes</condition>
  <arm_group>
    <arm_group_label>Lung cancer patients</arm_group_label>
    <description>Lung cancer patients in stages IA-IIIA destined to have stereotactic radiotherapy or conventional radiotherapy and chemotherapy in curative intent</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic or conventional radiotherapy and chemotherapy in curative intent</intervention_name>
    <arm_group_label>Lung cancer patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        lung cancer patients in stages IA-IIIA&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  Current lung cancer, not older than 8 weeks&#xD;
&#xD;
          -  Received written consent&#xD;
&#xD;
          -  Non small cell lung cancer&#xD;
&#xD;
          -  Stage IA-IIIA&#xD;
&#xD;
          -  Inoperable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of consent&#xD;
&#xD;
          -  Operable&#xD;
&#xD;
          -  Additional cancer disease&#xD;
&#xD;
          -  Small cell lung carcinoma or neuroendocrine lung cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vestfold Hospital Trust</name>
      <address>
        <city>TÃ¸nsberg</city>
        <zip>3103</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 15, 2015</study_first_submitted>
  <study_first_submitted_qc>April 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2015</study_first_posted>
  <last_update_submitted>May 2, 2021</last_update_submitted>
  <last_update_submitted_qc>May 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sykehuset i Vestfold HF</investigator_affiliation>
    <investigator_full_name>Janna Berg</investigator_full_name>
    <investigator_title>consultant</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

